Multiple generic versions of UCB’s €1.13bn ($1.25bn) Vimpat (lacosamide) tablets have been approved by the US Food and Drug Administration in all four strengths after the sole patent shielding the branded treatment of seizures expired.
The end of US reissued patent RE38,551’s term on 17 March has resulted in eight simultaneous ANDA approvals for lacosamide...